November 5, 2026

The Manager – Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sirs/ Madam,

Sub: Press Release

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

In line with Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release for the quarter and half year ended September 30, 2026.

Thanking you,

For **AstraZeneca Pharma India Limited**

TANYA SANISH
Digitally signed by TANYA SANISH
Date: 2026.11.05 19:28:14 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer
ACS No.: A25784

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited marks continued growth and strong commercial performance

30% growth as the Company announces Q2 results; total revenue from operations reaches INR 7,291 Mn.
Three new regulatory approvals in Q2 reinforces our leadership across therapy areas.

Mumbai, 5th November 2026: AstraZeneca Pharma India Limited ("the Company"), a science-led biopharmaceutical company, announced its second quarter (July 2026 - September 2026) financial results today. The Company reported strong growth of 30% for Q2 FY'26-27, supported by consistent performance across therapy areas it is present in - Oncology, Biopharmaceuticals, and Rare Disease. With that total revenue from operations in H1 2026-27 reaches INR 14,119 Mn growing by 30% from last financial year.

This performance reflects **disciplined execution**, **strong operational efficiency**, **continued portfolio expansion**, and **increasing adoption of innovative therapies that address unmet patient needs in India**.

Financial performance Summary:

Summary	Q2 2026-27 Jul'26 – Sep'26	H1 2026-27 Apr'26 – Sep'26	Q2 2025 - 26 Jul'25- Sep'25	H1 2025 - 26 Apr'25 - Sep'25
Total revenue from Operations	7,291	14,119	5,591	10,854
Oncology	5,085	9,733	3,978	7,674
Biopharmaceuticals (CVRM, R&I and V&I)	1,610	3,229	1,268	2,458
Rare Diseases	204	347	38	42

Mr. Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca Pharma India Ltd., said *"The continued growth demonstrates the strength of AstraZeneca's science-led portfolio and our ability to translate innovation into meaningful impact for patients in India. We are accelerating our efforts across oncology, biopharmaceuticals and rare disease. Our focus remains on building strong partnerships across the healthcare ecosystem to bring innovative medicines to more patients faster and improve health outcomes across the country."*

Key approvals:

- **Trastuzumab deruxtecan:** Received regulatory approval for Trastuzumab Deruxtecan followed by taxane, trastuzumab, and pertuzumab (THP) for adults with HER2-positive Stage II or III early breast cancer
- **Trastuzumab deruxtecan:** Received regulatory approval for Trastuzumab Deruxtecan for adults with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment
- **Trastuzumab deruxtecan:** Received regulatory approval for trastuzumab Deruxtecan in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+ or ISH+) breast cancer.
- **Benralizumab:** Received regulatory approval for Benralizumab, indicated for the treatment for patients aged 12 years and older with hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
- **Acalabrutinib:** Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL); Received regulatory approval for acalabrutinib in combination with venetoclax with or without obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL)
- **Acalabrutinib:** Received regulatory approval for acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL)

who are not eligible for autologous stem cell transplant (ASCT).

Strategic Initiatives:

- **MoU with the state of Andhra Pradesh to advance, first of its kind, 360-degree Oncology Care Model:** Signed a Memorandum of Understanding with the Government of Andhra Pradesh to support the state in building a 360-degree oncology care model focused on early detection and personalised treatment, and partner to establish a first-of-its-kind 'Integrated Genomic Solutions Centre (IGSC)' for NGS-based biomarker testing in lung and breast cancers. AstraZeneca will also facilitate the integration of AI-powered chest X-ray solution into routine public health workflows across the state, helping bring advanced diagnostics closer to patients.
- **MoU with state of Telangana to advance AI-enabled lung cancer screening:** Signed a Memorandum of Understanding with the Government of Telangana to introduce AI-enabled lung cancer screening across public healthcare facilities in the state. Under the collaboration, AstraZeneca will facilitate deployment of Qure.ai's AI-powered chest X-ray solution to support clinicians in identifying high-risk pulmonary nodules and other lung conditions, enabling earlier triage and follow-up. The initiative is expected to roll out across 20 public health facilities spanning urban and rural settings and includes training and upskilling of healthcare professionals to support effective and sustainable adoption.
- **K+ Connect – Hyperkalaemia management in Heart Failure and Chronic Kidney Disease:** Launched K+ Connect, a pan-India multidisciplinary initiative focused on advancing the management of hyperkalaemia among patients living with heart failure and chronic kidney disease. The initiative brings together clinicians across specialties to support a more coordinated approach towards risk identification, monitoring and management of hyperkalaemia.
- **India Coronary Conquest (ICC) 2026 – Advancing cardiovascular care:** Launched India Coronary Conquest 2026 in collaboration with STEMI India, a clinician-led national complex PCI challenge designed to strengthen evidence-based learning and peer exchange among interventional cardiologists. The initiative aims to support capability building in advanced cardiovascular care through case-based learning and scientific collaboration.

Recognitions:

- **OPPI India Awards 2026:** AstraZeneca Pharma India received the **Medical Excellence Award for its contributions to Rare Disease** and was named Runner-up in **the Marketing Excellence category for its Hyperkalaemia & Kidney Care initiative in Biopharmaceuticals.**
- **ETHRWorld Employee Experience Awards 2026:** AstraZeneca Pharma India was awarded the Gold Award in the Exceptional Employee Experience in Driving Business Impact category, recognising its commitment to fostering a high-performing, collaborative and purpose-driven workplace.

For media queries, please contact:
Pooja Behuria: pooja.behuria@astrazeneca.com
Gunjan Gupta: gunjan.gupta@astrazeneca.com